aranidipine

06/01/2000 - "Glomerular sclerosis, however, was less pronounced in the aranidipine-treated group than in the M-1 group. "
06/01/2000 - "The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. "

06/01/2000 - "The decreases in proteinuria were observed in the aranidipine-treated group at weeks 6, 8, and 10, whereas in the M-1 group, significant reduction was attained only at week 6. Histopathologic examination revealed that both treatments improved glomerular and arteriolar sclerosis. "

07/01/1993 - "Because of this cardiovascular profile, MPC-1304 should be useful in treatment of hypertension as well as angina pectoris."
01/01/1992 - "In conclusion, MPC-1304 and its active metabolites have potent antihypertensive effects and cause slight tachycardia, and they may be useful in treating hypertension."
06/01/1996 - "These findings suggest that MPC-1304 possesses a genetic hypertension-dependent renal vasodilating action, unlike nifedipine and manidipine. "
05/01/1994 - "This chronic ingestion of MPC-1304 and nicardipine inhibited the development of hypertension and reduced the concentration of blood urea nitrogen, creatinine, triglyceride and total cholesterol in serum. "
06/24/2009 - "To address this issue at the molecular level, blocking effects of 14 kinds of DHPs (amlodipine, aranidipine, azelnidipine, barnidipine, benidipine, cilnidipine, efonidipine, felodipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nitrendipine), which are clinically used for treatments of hypertension, on 3 subtypes of T-type Ca(2+) channels [Ca(v)3.2 (alpha(1H)), Ca(v)3.3 (alpha(1I)), and Ca(v)3.1 (alpha(1G))] were investigated in the Xenopus oocyte expression system using the two-microelectrode voltage-clamp technique. "

10/22/2013 - "[Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension]."
09/01/2013 - "Administration of aranidipine enteric-coated capsules can control 24 h blood pressure effectively and reduce BPV significantly in patients with mild to moderate essential hypertension with good safety profile."
09/01/2013 - "To evaluate the effect of aranidipine enteric-coated capsules on 24 h blood pressure and blood pressure variability (BPV) in patients with mild to moderate essential hypertension. "
09/01/2013 - "[The effects of aranidipine on ambulatory blood pressures in patients with mild to moderate essential hypertension]."
10/22/2013 - "To assess the efficacy and safety of aranidipine versus retard-released felodipine in Chinese patients with mild-to-moderate essential hypertension. "

05/01/1994 - "Thus, MPC-1304 had antihypertensive effects in stroke-prone spontaneously hypertensive rats."
05/01/1994 - "Effects of MPC-1304, a novel calcium antagonist, on stroke-prone spontaneously hypertensive rats."
05/01/1994 - "Treatment with MPC-1304 inhibited the incidence of cerebral stroke, cardiac fibrosis, proliferative and fibrinoid arteriolitis and malignant nephrosclerosis. "
05/01/1994 - "The effects of MPC-1304, a newly developed 1,4-dihydropyridine derivative, on blood pressure and hypertensive complications in stroke-prone spontaneously hypertensive rats fed a high-salt diet (0.8% NaCl), were investigated. "